AstraZeneca’s COVID-19 vaccine has no efficacy against South African virus strains, study programs
According to a Phase 1b-2 trial published in the New England Journal of Medicine, the two-dose COVID-19 vaccine was developed by Oxford University / AstraZeneca Plc (NASDAQ: AZN) was ineffective ag…
